• Wenjun Yu, Jianyong Li, and Lijuan Chen.
• Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital Nanjing, China.
• Int J Clin Exp Med. 2014 Jan 1; 7 (11): 4051-62.

AbstractCytogenetic abnormalities have emerged as the major novel prognostic factors in multiple myeloma (MM) patients. This meta-analysis comprehensively investigates the association between the cytogenetic abnormalities and survival of MM patients. We searched the PubMed, EMBASE, SCOPUS, and Cochrane databases for articles published until February, 2014. Thirty eligible studies involving 10276 patients were included to examine the association of three chromosomal abnormalities, t (4; 14), del (17p), and Amp (1q21), with survival in MM patients. The main outcome measures were progression-free survival (PFS) and overall survival (OS). Individuals with t (4; 14), del (17p), and Amp (1q21) had low OS and PFS. In a subgroup analysis for therapy regimen, lenalidomide- and bortezomib-based therapies increased the PFS of patients with Amp (1q21) (HR=1.50, 95% CI=0.95-2.36, p=0.084) and t (4; 14) (HR=1.38, 95% CI=0.90-2.11, p=0.143). The presence of del (17p) elicited no significant influence on the prognosis of patients under different therapy regimens. Our meta-analysis provides globally quantifiable confirmation of the adverse prognostic value of t (4; 14), del (17p), and Amp (1q21) in OS and PFS for MM patients. Lenalidomide- and bortezomib-based therapies were partly conducive to improve the prognosis of individuals with t (4; 14). Bortezomib-based therapy can partly improve the PFS of patients with Amp (1q21).

6 keywords...

hide…